{"id":29126,"date":"2025-11-10T14:40:21","date_gmt":"2025-11-10T07:40:21","guid":{"rendered":"https:\/\/nhathuocngocanh.com\/bp\/?p=29126"},"modified":"2025-11-10T14:40:42","modified_gmt":"2025-11-10T07:40:42","slug":"ramipril","status":"publish","type":"post","link":"https:\/\/nhathuocngocanh.com\/bp\/ramipril\/","title":{"rendered":"Ramipril"},"content":{"rendered":"

Edition: BP 2025 (Ph. Eur. 11.6 update)<\/p>\n

Action and use<\/strong><\/p>\n

Angiotensin converting enzyme inhibitor.<\/p>\n

Preparations<\/strong><\/p>\n

Ramipril Capsules Ramipril Tablets<\/p>\n

DEFINITION<\/h2>\n
(2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid.<\/p>\n
Content<\/strong><\/p>\n
98.0 per cent to 101.0 per cent (dried substance).<\/p>\n
CHARACTERS<\/h2>\n
Appearance<\/h3>\n
White or almost white, crystalline powder.<\/p>\n
Solubility<\/h3>\n
Sparingly soluble in water, freely soluble in methanol.<\/p>\n
IDENTIFICATION<\/h2>\n
A. Specific optical rotation (see Tests).<\/p>\n
B. Infrared absorption spectrophotometry (2.2.24).<\/p>\n
Comparison\u00a0 ramipril CRS.<\/p>\n
TESTS<\/h2>\n
Appearance of solution<\/h3>\n
The solution is clear (2.2.1) and colourless (2.2.2, Method II).<\/h4>\n
Dissolve 0.1 g in methanol R and dilute to 10.0 mL with the same solvent.<\/p>\n
Specific optical rotation (2.2.7)<\/h4>\n
+ 32.0 to + 38.0 (dried substance).<\/p>\n
Dissolve 0.250 g in a mixture of 14 volumes of hydrochloric acid R1 and 86 volumes of methanol R and dilute to 25.0 mL with the same mixture of solvents.<\/p>\n
Related substances<\/h3>\n
Liquid chromatography (2.2.29).<\/p>\n
Test solution Dissolve 20 mg of the substance to be examined in mobile phase A and dilute to 20.0 mL with mobile phase A.<\/p>\n
Reference solution (a) Dissolve 2 mg of ramipril impurity A CRS, 2 mg of ramipril impurity B CRS, 2 mg of ramipril impurity C CRS and 2 mg of ramipril impurity D CRS in mobile phase A and dilute to 25 mL with mobile phase A. To 1 mL of this solution, add 5 mL of the test solution and dilute to 10 mL with mobile phase B.<\/p>\n
Reference solution (b)\u00a0 Dilute 5.0 mL of the test solution to 100.0 mL with mobile phase B. Dilute 5.0 mL of this solution to 50.0 mL with mobile phase B.<\/p>\n
Reference solution (c)\u00a0 Dilute 1.0 mL of reference solution (b) to 10.0 mL with mobile phase B.<\/p>\n
Column:<\/p>\n
\u2014 size: l = 0.25 m, \u00d8 = 4.0 mm;<\/p>\n
\u2014 stationary phase: end-capped octadecylsilyl silica gel for chromatography R (3 \u00b5m);<\/p>\n
\u2014 temperature: 65 \u00b0C.<\/p>\n
Mobile phase:<\/p>\n
\u2014 mobile phase A: dissolve 2.0 g of sodium perchlorate R in a mixture of 0.5 mL of triethylamine R and 800 mL of water for chromatography R; adjust to pH 3.6 with phosphoric acid R and add 200 mL of acetonitrile R1;<\/p>\n
\u2014 mobile phase B: dissolve 2.0 g of sodium perchlorate R in a mixture of 0.5 mL of triethylamine R and 300 mL of water for chromatography R; adjust to pH 2.6 with phosphoric acid R and add 700 mL of acetonitrile R1;<\/p>\n\n\n\n\n\n\n\n\n
Time (min)<\/td>\n Mobile phase A (per cent V\/V)<\/td>\n Mobile phase B (per cent V\/V)<\/td>\n<\/tr>\n
0 – 6<\/td>\n 90<\/td>\n 10<\/td>\n<\/tr>\n
6 – 7<\/td>\n 90 \u2192 75<\/td>\n 10 \u2192 25<\/td>\n<\/tr>\n
7 – 20<\/td>\n 75 \u2192 65<\/td>\n 25 \u2192 35<\/td>\n<\/tr>\n
20 – 30<\/td>\n 65 \u2192 25<\/td>\n 35 \u2192 75<\/td>\n<\/tr>\n
30 – 50<\/td>\n 20<\/td>\n 75<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
Flow rate\u00a0 1.0 mL\/min.<\/p>\n
Detection\u00a0 Spectrophotometer at 210 nm.<\/p>\n
Equilibration With the mobile phase at the initial composition for at least 35 min; if a suitable baseline cannot be obtained, use another grade of triethylamine.<\/p>\n
Injection\u00a0 10 \u00b5L.<\/p>\n
Identification of impurities Use the chromatogram obtained with reference solution (a) to identify the peaks due to impurities A, B, C and D.<\/p>\n
Relative retention\u00a0 With reference to ramipril (retention time = about 18 min): impurity A = about 0.8; impurity B = about 1.3; impurity C = about 1.5; impurity D = about 1.7.<\/p>\n
System suitability:<\/p>\n
\u2014 resolution: minimum 3.0 between the peaks due to impurity A and ramipril in the chromatogram obtained with reference solution (a);<\/p>\n
\u2014 signal-to-noise ratio: minimum 3 for the principal peak in the chromatogram obtained with reference solution (c);<\/p>\n
\u2014 symmetry factor: 0.8 to 2.0 for the peak due to ramipril in the chromatogram obtained with the test solution.<\/p>\n
Limits:<\/p>\n
\u2014 correction factor: for the calculation of content, multiply the peak area of impurity C by 2.4;<\/p>\n
\u2014 impurities A, B, C, D: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);<\/p>\n
\u2014 unspecified impurities: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);<\/p>\n
\u2014 total: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent);<\/p>\n
\u2014 disregard limit: the area of the principal peak in the chromatogram obtained with reference solution (c) (0.05 per cent).<\/p>\n
Loss on drying (2.2.32)<\/h4>\n
Maximum 0.2 per cent, determined on 1.000 g by drying in vacuo at 60 \u00b0C at a pressure not exceeding 0.1 kPa for 4 h.<\/p>\n
Sulfated ash (2.4.14)<\/h4>\n
Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n
ASSAY<\/h2>\n
Dissolve 0.300 g in 25 mL of methanol R and add 25 mL of water R. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.2.20). Carry out a blank titration.<\/p>\n
1 mL of 0.1 M sodium hydroxide is equivalent to 41.65 mg of C_{23<\/sub>H_{32<\/sub>N_{2<\/sub>O_{5<\/sub>.<\/p>\n}}}}
STORAGE<\/h2>\n
Protected from light.<\/p>\n
IMPURITIES<\/h2>\n
Specified impurities\u00a0 A, B, C, D.<\/em><\/p>\n
Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) E, F, G, H, I, J, K, L, M, N, O.<\/em><\/p>\n
A. (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-methoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid (ramipril methyl ester),<\/p>\n
B. (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-oxo-4-phenyl-1-[(propan2-yl)oxy]butan-2- yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramipril isopropyl ester),<\/p>\n
C. (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-4-cyclohexyl-1-ethoxy-1oxobutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-\u00a0 2-carboxylic acid (hexahydroramipril),<\/p>\n
D. ethyl (2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl]-4- phenylbutanoate (ramipril diketopiperazine),<\/p>\n
E. (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramiprilat),<\/p>\n
F. (2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid,<\/p>\n
G. methylbenzene (toluene),<\/p>\n
H. (2S,3aS,6aS)-1-[(2S)-2-[[(2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid ((R,S,S,S,S)-epimer of ramipril),<\/p>\n
I. (2S,3aS,6aS)-1-[(2R)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid ((S,R,S,S,S)-epimer of ramipril),<\/p>\n
J. (2R,3aR,6aR)-1-[(2R)-2-[[(2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid (enantiomer of ramipril),<\/p>\n
K. (2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl]-4- phenylbutanoic acid (ramiprilate diketopiperazine),<\/p>\n
L. ethyl (2S)-2-[(3S,5aS,8aS,9aS)-9a-hydroxy-3-methyl-1,4-dioxodecahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2- yl]-4-phenylbutanoate (ramipril hydroxydiketopiperazine),<\/p>\n
M. (2R,3R)-2,3-bis(benzoyloxy)butanedioic acid (dibenzoyl tartric acid),<\/p>\n
N. (2R,3aR,6aR)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid ((S,S,R,R,R)-isomer of ramipril),<\/p>\n
O. diethyl (2\u039e,2\u2032\u039e)-2,2\u2032-[(2\u039e,5\u039e)-2,5-dimethyl-3,6-dioxopiperazine-1,4-diyl]bis(4-phenylbutanoate).<\/p>\n","protected":false},"excerpt":{"rendered":"
Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Angiotensin converting enzyme inhibitor. Preparations Ramipril Capsules Ramipril Tablets DEFINITION (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid. Content 98.0 per cent to 101.0 per cent (dried substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Sparingly soluble in water, freely soluble in methanol. IDENTIFICATION A. Specific optical rotation…<\/p>\n","protected":false},"author":5,"featured_media":29132,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-29126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/29126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=29126"}],"version-history":[{"count":3,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/29126\/revisions"}],"predecessor-version":[{"id":29139,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/29126\/revisions\/29139"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/29132"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=29126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=29126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=29126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Time (min)<\/td>\n	Mobile phase A (per cent V\/V)<\/td>\n	Mobile phase B (per cent V\/V)<\/td>\n<\/tr>\n
0 – 6<\/td>\n	90<\/td>\n	10<\/td>\n<\/tr>\n
6 – 7<\/td>\n	90 \u2192 75<\/td>\n	10 \u2192 25<\/td>\n<\/tr>\n
7 – 20<\/td>\n	75 \u2192 65<\/td>\n	25 \u2192 35<\/td>\n<\/tr>\n
20 – 30<\/td>\n	65 \u2192 25<\/td>\n	35 \u2192 75<\/td>\n<\/tr>\n
30 – 50<\/td>\n	20<\/td>\n	75<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Flow rate\u00a0 1.0 mL\/min.<\/p>\n Detection\u00a0 Spectrophotometer at 210 nm.<\/p>\n Equilibration With the mobile phase at the initial composition for at least 35 min; if a suitable baseline cannot be obtained, use another grade of triethylamine.<\/p>\n Injection\u00a0 10 \u00b5L.<\/p>\n Identification of impurities Use the chromatogram obtained with reference solution (a) to identify the peaks due to impurities A, B, C and D.<\/p>\n Relative retention\u00a0 With reference to ramipril (retention time = about 18 min): impurity A = about 0.8; impurity B = about 1.3; impurity C = about 1.5; impurity D = about 1.7.<\/p>\n System suitability:<\/p>\n \u2014 resolution: minimum 3.0 between the peaks due to impurity A and ramipril in the chromatogram obtained with reference solution (a);<\/p>\n \u2014 signal-to-noise ratio: minimum 3 for the principal peak in the chromatogram obtained with reference solution (c);<\/p>\n \u2014 symmetry factor: 0.8 to 2.0 for the peak due to ramipril in the chromatogram obtained with the test solution.<\/p>\n Limits:<\/p>\n \u2014 correction factor: for the calculation of content, multiply the peak area of impurity C by 2.4;<\/p>\n \u2014 impurities A, B, C, D: for each impurity, not more than the area of the principal peak in the chromatogram obtained with reference solution (b) (0.5 per cent);<\/p>\n \u2014 unspecified impurities: for each impurity, not more than 0.2 times the area of the principal peak in the chromatogram obtained with reference solution (b) (0.10 per cent);<\/p>\n \u2014 total: not more than twice the area of the principal peak in the chromatogram obtained with reference solution (b) (1.0 per cent);<\/p>\n \u2014 disregard limit: the area of the principal peak in the chromatogram obtained with reference solution (c) (0.05 per cent).<\/p>\n Loss on drying (2.2.32)<\/h4>\n Maximum 0.2 per cent, determined on 1.000 g by drying in vacuo at 60 \u00b0C at a pressure not exceeding 0.1 kPa for 4 h.<\/p>\n Sulfated ash (2.4.14)<\/h4>\n Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n ASSAY<\/h2>\n Dissolve 0.300 g in 25 mL of methanol R and add 25 mL of water R. Titrate with 0.1 M sodium hydroxide, determining the end-point potentiometrically (2.2.20). Carry out a blank titration.<\/p>\n 1 mL of 0.1 M sodium hydroxide is equivalent to 41.65 mg of C_{23<\/sub>H_{32<\/sub>N_{2<\/sub>O_{5<\/sub>.<\/p>\n}}}} STORAGE<\/h2>\n Protected from light.<\/p>\n IMPURITIES<\/h2>\n Specified impurities\u00a0 A, B, C, D.<\/em><\/p>\n Other detectable impurities (the following substances would, if present at a sufficient level, be detected by one or other of the tests in the monograph. They are limited by the general acceptance criterion for other\/unspecified impurities and\/or by the general monograph Substances for pharmaceutical use (2034). It is therefore not necessary to identify these impurities for demonstration of compliance. See also 5.10. Control of impurities in substances for pharmaceutical use) E, F, G, H, I, J, K, L, M, N, O.<\/em><\/p>\n A. (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-methoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid (ramipril methyl ester),<\/p>\n B. (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-oxo-4-phenyl-1-[(propan2-yl)oxy]butan-2- yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramipril isopropyl ester),<\/p>\n C. (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-4-cyclohexyl-1-ethoxy-1oxobutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-\u00a0 2-carboxylic acid (hexahydroramipril),<\/p>\n D. ethyl (2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl]-4- phenylbutanoate (ramipril diketopiperazine),<\/p>\n E. (2S,3aS,6aS)-1-[(2S)-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (ramiprilat),<\/p>\n F. (2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoic acid,<\/p>\n G. methylbenzene (toluene),<\/p>\n H. (2S,3aS,6aS)-1-[(2S)-2-[[(2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid ((R,S,S,S,S)-epimer of ramipril),<\/p>\n I. (2S,3aS,6aS)-1-[(2R)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid ((S,R,S,S,S)-epimer of ramipril),<\/p>\n J. (2R,3aR,6aR)-1-[(2R)-2-[[(2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid (enantiomer of ramipril),<\/p>\n K. (2S)-2-[(3S,5aS,8aS,9aS)-3-methyl-1,4-dioxodecahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2-yl]-4- phenylbutanoic acid (ramiprilate diketopiperazine),<\/p>\n L. ethyl (2S)-2-[(3S,5aS,8aS,9aS)-9a-hydroxy-3-methyl-1,4-dioxodecahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-2- yl]-4-phenylbutanoate (ramipril hydroxydiketopiperazine),<\/p>\n M. (2R,3R)-2,3-bis(benzoyloxy)butanedioic acid (dibenzoyl tartric acid),<\/p>\n N. (2R,3aR,6aR)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid ((S,S,R,R,R)-isomer of ramipril),<\/p>\n O. diethyl (2\u039e,2\u2032\u039e)-2,2\u2032-[(2\u039e,5\u039e)-2,5-dimethyl-3,6-dioxopiperazine-1,4-diyl]bis(4-phenylbutanoate).<\/p>\n","protected":false},"excerpt":{"rendered":" Edition: BP 2025 (Ph. Eur. 11.6 update) Action and use Angiotensin converting enzyme inhibitor. Preparations Ramipril Capsules Ramipril Tablets DEFINITION (2S,3aS,6aS)-1-[(2S)-2-[[(2S)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]octahydrocyclopenta[b]pyrrole-2- carboxylic acid. Content 98.0 per cent to 101.0 per cent (dried substance). CHARACTERS Appearance White or almost white, crystalline powder. Solubility Sparingly soluble in water, freely soluble in methanol. IDENTIFICATION A. Specific optical rotation…<\/p>\n","protected":false},"author":5,"featured_media":29132,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[174],"tags":[],"class_list":["post-29126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-medicinal-substances"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/29126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=29126"}],"version-history":[{"count":3,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/29126\/revisions"}],"predecessor-version":[{"id":29139,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/29126\/revisions\/29139"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/29132"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=29126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=29126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=29126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Appearance<\/h3>\nWhite or almost white, crystalline powder.<\/p>\n

Solubility<\/h3>\nSparingly soluble in water, freely soluble in methanol.<\/p>\n

IDENTIFICATION<\/h2>\nA. Specific optical rotation (see Tests).<\/p>\nB. Infrared absorption spectrophotometry (2.2.24).<\/p>\nComparison\u00a0 ramipril CRS.<\/p>\n

TESTS<\/h2>\n

Appearance of solution<\/h3>\n

The solution is clear (2.2.1) and colourless (2.2.2, Method II).<\/h4>\nDissolve 0.1 g in methanol R and dilute to 10.0 mL with the same solvent.<\/p>\n

Specific optical rotation (2.2.7)<\/h4>\n+ 32.0 to + 38.0 (dried substance).<\/p>\nDissolve 0.250 g in a mixture of 14 volumes of hydrochloric acid R1 and 86 volumes of methanol R and dilute to 25.0 mL with the same mixture of solvents.<\/p>\n

Loss on drying (2.2.32)<\/h4>\nMaximum 0.2 per cent, determined on 1.000 g by drying in vacuo at 60 \u00b0C at a pressure not exceeding 0.1 kPa for 4 h.<\/p>\n

Sulfated ash (2.4.14)<\/h4>\nMaximum 0.1 per cent, determined on 1.0 g.<\/p>\n

STORAGE<\/h2>\nProtected from light.<\/p>\n

Appearance<\/h3>\n
White or almost white, crystalline powder.<\/p>\n

Solubility<\/h3>\n
Sparingly soluble in water, freely soluble in methanol.<\/p>\n

IDENTIFICATION<\/h2>\n
A. Specific optical rotation (see Tests).<\/p>\n
B. Infrared absorption spectrophotometry (2.2.24).<\/p>\n
Comparison\u00a0 ramipril CRS.<\/p>\n

The solution is clear (2.2.1) and colourless (2.2.2, Method II).<\/h4>\n
Dissolve 0.1 g in methanol R and dilute to 10.0 mL with the same solvent.<\/p>\n

Specific optical rotation (2.2.7)<\/h4>\n
+ 32.0 to + 38.0 (dried substance).<\/p>\n
Dissolve 0.250 g in a mixture of 14 volumes of hydrochloric acid R1 and 86 volumes of methanol R and dilute to 25.0 mL with the same mixture of solvents.<\/p>\n

Loss on drying (2.2.32)<\/h4>\n
Maximum 0.2 per cent, determined on 1.000 g by drying in vacuo at 60 \u00b0C at a pressure not exceeding 0.1 kPa for 4 h.<\/p>\n

Sulfated ash (2.4.14)<\/h4>\n
Maximum 0.1 per cent, determined on 1.0 g.<\/p>\n

STORAGE<\/h2>\n
Protected from light.<\/p>\n